Zacks Research Issues Pessimistic Estimate for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Research analysts at Zacks Research lowered their Q1 2026 earnings estimates for Bio-Rad Laboratories in a report released on Monday, March 2nd. Zacks Research analyst Team now anticipates that the medical research company will post earnings of $2.77 per share for the quarter, down from their previous forecast of $2.79. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2026 earnings at $2.34 EPS, Q4 2026 earnings at $2.59 EPS, FY2026 earnings at $10.32 EPS, Q1 2027 earnings at $2.22 EPS, Q2 2027 earnings at $2.30 EPS, Q3 2027 earnings at $2.35 EPS and FY2027 earnings at $9.30 EPS.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The business had revenue of $693.20 million for the quarter, compared to the consensus estimate of $694.64 million. During the same period in the prior year, the business posted $2.90 EPS. Bio-Rad Laboratories’s revenue for the quarter was up 3.9% on a year-over-year basis.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Stock Up 0.4%

BIO stock opened at $280.73 on Tuesday. The business has a 50 day moving average of $297.25 and a 200 day moving average of $301.46. The firm has a market cap of $7.58 billion, a PE ratio of 10.06 and a beta of 1.18. Bio-Rad Laboratories has a twelve month low of $211.43 and a twelve month high of $343.12. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16.

Institutional Trading of Bio-Rad Laboratories

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in Bio-Rad Laboratories during the fourth quarter valued at approximately $672,000. Corient Private Wealth LLC raised its stake in Bio-Rad Laboratories by 4,570.8% during the 4th quarter. Corient Private Wealth LLC now owns 66,792 shares of the medical research company’s stock valued at $20,237,000 after buying an additional 65,362 shares during the last quarter. Vident Advisory LLC bought a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at $892,000. State of Tennessee Department of Treasury boosted its stake in shares of Bio-Rad Laboratories by 35.1% in the 4th quarter. State of Tennessee Department of Treasury now owns 3,796 shares of the medical research company’s stock worth $1,115,000 after buying an additional 987 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in shares of Bio-Rad Laboratories by 9.1% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 259,577 shares of the medical research company’s stock worth $78,649,000 after acquiring an additional 21,674 shares during the period. 65.24% of the stock is currently owned by institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.